drugset

drugset / Trial / NCT03090737

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

NCT03090737 ↗

Phase 2 Completed 129 enrolled Bristol-Myers Squibb Ono Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Timeline

Start: 2017-06-02
Primary completion: 2021-02-16
Completion: 2022-03-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	—	—

Indications